CAPZB

Across TCGA pan-cancer cohorts, CAPZB Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated CAPZB data layer compared with 23 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in stomach adenocarcinoma (STAD), where higher CAPZB Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated CAPZB expression acts as an unfavorable survival marker, although some lineages such as HNSC show a favorable association.

STAD, SKCM, and HNSC are the cancer types where CAPZB Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
STAD	OS	Median	All	0.254	0.689	.006	24	view →
SKCM	DFS	Median	All	0.192	0.737	.016	12	view →
HNSC	DFS	Median	II,III,IV	1.000	0.312	.029	11	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

CAPZB–STAD (OS)

Open the STAD breakdown →